- PD-1/PD-L1 inhibitors were associated with median progression-free survival of 4.21 months and overall survival of 16.27 months in NPC.
- Response rates were moderate, with an objective response rate of 45% and disease control rate of 65%.
- Adverse events were common, occurring in 90% of patients, with 34% experiencing grade 3 or higher events.
- Results varied across studies, with substantial heterogeneity and sensitivity to individual trials.
- Most included studies were single-arm, limiting the strength of conclusions.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
